Bridgebio Pharma (BBIO) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
- Market cap
- $15B
- As of Nov 17, 2026
- P/E
- -26.46x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 15.85x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $15B
- As of Nov 17, 2026
- P/E
- -26.46x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 15.85x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-26.46x
Net loss — not comparable
P/B
—
P/S
15.85x
Earnings and dividend metrics▾
Earnings
EPS
-$2.90
Earnings per share
BPS
—
Book value per share
ROE
—
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $2.90 per share.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 191.7% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $121M+191.7%
$3M
Jul–Sep '24
$121M
Jul–Sep '25
$353M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 191.7% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Apuli MaricelChief Accounting Officer · Oct 30, 2026Open-market sale2,000 shares · $146KAvg. price $72.85120,687 shares held after
- Kumar NeilChief Executive Officer · Sep 17, 2026Open-market sale10,000 shares · $691KAvg. price $69.0847
Show 2 price lots
- 8,721 shares × $69.0136$602K
- 1,279 shares × $69.5696$89K
- Kumar NeilChief Executive Officer · Aug 19, 2026Open-market sale10,000 shares · $840KAvg. price $84.0257
Show 3 price lots
- 8,100 shares × $83.8588$679K
- 1,800 shares × $84.6867$152K
- 100 shares × $85.65$9K
- Kumar NeilChief Executive Officer · Aug 18, 2026Open-market sale34,980 shares · $2.9MAvg. price $82.5327
Show 4 price lots
- 17,279 shares × $82.2104$1.4M
- 14,602 shares × $82.9922$1.2M
- 1,900 shares × $81.1494$154K
- 1,199 shares × $83.7732$100K
- Kumar NeilChief Executive Officer · Aug 16, 2026Shares withheld for taxes36,237 shares · $2.9MAvg. price $79.86278,307 shares held after
- Trimarchi ThomasPresident and CFO · Aug 16, 2026Shares withheld for taxes22,781 shares · $1.8MAvg. price $79.86336,529 shares held after
- Apuli MaricelChief Accounting Officer · Aug 16, 2026Shares withheld for taxes4,714 shares · $376KAvg. price $79.86122,687 shares held after
- Kumar NeilChief Executive Officer · Aug 16, 2026Option exercise71,217 shares
Show 4 price lots
- 6,520 sharesValue not reported
- 11,554 sharesValue not reported
- 19,599 sharesValue not reported
- 33,544 sharesValue not reported
- Apuli MaricelChief Accounting Officer · Jul 30, 2026Open-market sale2,000 shares · $160KAvg. price $80.06127,401 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Bridgebio Pharma (BBIO) stock information
NASDAQ
Bridgebio Pharma (BBIO) is listed on NASDAQ. Its market capitalization is about $15B. On trailing-twelve-month earnings the P/E ratio is -26.46. These figures are computed in-house from official filings and are reference information only.
Bridgebio Pharma — frequently asked questions
- What is the P/E ratio of Bridgebio Pharma (BBIO)?
- On a trailing-twelve-month basis, BBIO trades at a P/E ratio of -26.46. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Bridgebio Pharma?
- BBIO has a market capitalization of about $15B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.